C8 Sciences is a pioneering digital therapeutics company that has developed the most comprehensive neuroscience-based technology for remediating the cognitive dysfunction associated with CNS disorders. In three clinical studies with major depression patients, our technology demonstrated significant cognitive function improvements in treatment-resistant adults that then drove reductions in their depressed mood symptoms superior to pharmacotherapy, cognitive behavioral therapy, and other digital therapy interventions. We have also demonstrated our product’s mechanism of action through normalization of the decreased functional connectivity seen in depressed patients on fMRI. In addition, our technology generates the most comprehensive, fine-grained set of neurocognitive brain function measures available, enabling highly specific biomarkers for diagnostic, prognostic, and longitudinal monitoring applications across a spectrum of CNS disorders. As a remotely-delivered therapy, our system is particularly well-suited for underrepresented and older-age communities where access and/or cost are significant barriers to treatment. C8's advanced products target CNS-related symptoms that afflict over one billion people, including those with chronic illnesses, which are often accompanied by co-morbid depression or cognitive impairments that limit both quality and duration of life.

Acquired by Allied Signal/Honeywell